Skip to content
Yog Pharma

Tadalafil is a PDE5 inhibitor indicated for erectile dysfunction, benign prostatic hyperplasia and pulmonary arterial hypertension. We supply it to US manufacturers of tablets and oral suspension.

CAS171596-29-5389.4 g/molC22H19N3O4
2D structure of Tadalafil.

Data from PubChem (CID 110635) and FDA’s substance registry

CAS number

171596-29-5

Molecular formula

C22H19N3O4

Molecular weight

389.4g/mol

FDA UNII

IUPAC name

(2R,8R)-2-(1,3-benzodioxol-5-yl)-6-methyl-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione

InChIKey

WOXKDUGGOYFFRN-IIBYNOLFSA-N

Appearance
White or almost white powder.
Solubility
Practically insoluble in water, freely soluble in dimethyl sulfoxide and slightly soluble in methylene chloride.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Micronized material is standard. It has two chiral centers, so check the limits for the other stereoisomers.

On the US market

Reference product
CialisNDA 021368
Approved ANDAs
39 with a marketed product
Approved forms and strengths
  • Tablet 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg
  • Oral suspension 20 mg/5 mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com